Well & Well Pharma Pvt.Ltd
Private pharmaceutical manufacturer · Rawat · Pakistan
Rawat-based pharmaceutical manufacturer producing general and cephalosporin products and operating as a subsidiary of Well & Well Pharma UK Ltd.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Well & Well Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Plot 7, Street S-8, RCCI National Industrial Zone, Rawat, Islamabad, Pakistan
- Website
- wellnwell.com ↗
- Phone
- +92 301 8185197
- info@wellnwell.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Bisovel | Bisoprolol fumarate | 10 mg | Tablet | 2x10's | 095338 | PKR 415.49 | PKR 20.77/tablet | 6% below median |
| Bisovel | Bisoprolol fumarate | 2.5 mg | Tablet | 14's | 095339 | PKR 55.39 | PKR 3.96/tablet | 7% below median |
| Bisovel | Bisoprolol fumarate | 5 mg | Tablet | 2x10's | 095340 | PKR 230.82 | PKR 11.54/tablet | Near median |
| Calssica | Ceftriaxone | 250 mg | Powder for injection | 1's | 098385 | PKR 186.50 | PKR 186.50/vial/unit | Near median |
| Calssica | Ceftriaxone | 500 mg | IV injection | 1's | 098386 | PKR 313.92 | PKR 313.92/vial/unit | Near median |
| Calssica | Ceftriaxone | 500 mg | Powder for injection | 1's | 098386 | PKR 313.92 | PKR 313.92/vial/unit | Near median |
| Calssica | Ceftriaxone | 1 g | Powder for injection | 1's | 098387 | PKR 592.76 | PKR 592.76/vial/unit | Near median |
| Calssica | Ceftriaxone | 250 mg | Powder for injection | 1's | 098388 | PKR 186.50 | PKR 186.50/vial/unit | Near median |
| Calssica | Ceftriaxone | 500 mg | IM injection | 1's | 098389 | PKR 313.92 | PKR 313.92/vial/unit | Near median |
| Calssica | Ceftriaxone | 500 mg | Powder for injection | 1's | 098389 | PKR 313.92 | PKR 313.92/vial/unit | Near median |
| Carezole | Metronidazole (Benzoate) | 500 mg/100 mL | IV infusion | 100ml | 119034 | PKR 155.59 | PKR 1.56/mL | 16% below median |
| Cefivel | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 085324 | PKR 384.55 | PKR 12.82/mL | Near median |
| Cefivel | Cefixime | 100 mg/5 mL | Dry suspension | 30ml | 085325 | PKR 314.24 | PKR 10.47/mL | Near median |
| Cefivel | Cefixime | 400 mg | Capsule | 5's | 085326 | PKR 563.10 | PKR 112.62/capsule | Near median |
| Cefravel | Cefoperazone | 1 g | Powder for injection | 1's | 097539 | PKR 415.49 | PKR 415.49/vial/unit | No comparator |
| Cephzin | Cephalexin | 500 mg | Capsule | 12's | 093324 | PKR 369.31 | PKR 30.78/capsule | Near median |
| Cephzin | Cephalexin | 250 mg | Capsule | 12's | 093325 | PKR 188.36 | PKR 15.70/capsule | Near median |
| Cephzin | Cephalexin | 250 mg/5 mL | Dry suspension | 60ml | 093333 | PKR 188.36 | PKR 3.14/mL | 10% above median |
| Cephzin | Cephalexin | 125 mg/5 mL | Dry suspension | 60ml | 093334 | PKR 108.94 | PKR 1.82/mL | Near median |
| Cipnolone | Ciprofloxacin | 250 mg | Tablet | 10's | 065127 | PKR 247.05 | PKR 24.71/tablet | Near median |
| Cipnolone | Ciprofloxacin | 500 mg | Tablet | 10's | 065128 | PKR 408.58 | PKR 40.86/tablet | Near median |
| Cipnolone | Ciprofloxacin | 750 mg | Tablet | 10's | 065129 | PKR 380.06 | PKR 38.01/tablet | 5% below median |
| Cipnolone | Ciprofloxacin | 250 mg/5 mL | Suspension | 60ml | 070067 | PKR 304.05 | PKR 5.07/mL | Near median |
| Cipnolone | Ciprofloxacin | 125 mg/5 mL | Suspension | 60ml | 077803 | PKR 169.65 | PKR 2.83/mL | 20% below median |
| Cipnolone | Ciprofloxacin | 200 mg/100 mL | Injection | 100ml vial | 119497 | PKR 206.53 | PKR 2.07/mL | 17% above median |
| Clarivel | Clarithromycin | 250 mg | Tablet | 10's | 065119 | PKR 452.39 | PKR 45.24/tablet | Near median |
| Clarivel | Clarithromycin | 500 mg | Tablet | 10's | 065120 | PKR 838.82 | PKR 83.88/tablet | Near median |
| Clarivel | Clarithromycin | 125 mg/5 mL | Suspension | 60ml | 065298 | PKR 420.35 | PKR 7.01/mL | 5% below median |
| Clopivel | Clopidogrel | 75 mg | Tablet | 10's | 085749 | PKR 263.90 | PKR 26.39/tablet | Near median |
| Empel 40mg injectionRegistry verified | Esomeprazole | — | — | — | 119032Official source ↗ | No indexed price | — | — |
| Erythrovel | Erythromycin | 500 mg | Tablet | 1x10's | 081683 | PKR 98.02 | PKR 9.80/tablet | 19% above median |
| Ferovel ………Source observed | Iron | 150 mg | Capsule | 1x10`s | 065290Official source ↗ | No indexed price | — | — |
| Fungvel | Fluconazole | 150 mg | Capsule | 1's | 065295 | PKR 260.12 | PKR 260.12/capsule | Near median |
| Fungvel | Fluconazole | 50 mg/5 mL | Dry suspension | 35ml | 095344 | PKR 387.78 | PKR 11.08/mL | 6% below median |
| Lefnil | Levofloxacin | 250 mg | Tablet | 10's | 065123 | PKR 475.48 | PKR 47.55/tablet | Near median |
| Lefnil | Levofloxacin | 500 mg | Tablet | 10's | 065124 | PKR 790.53 | PKR 79.05/tablet | Near median |
| Lenzovel | Linezolid | 100 mg/5 mL | Dry suspension | 60ml | 095345 | PKR 646.31 | PKR 10.77/mL | Near median |
| Malavel | Artemether | 20 mg | Tablet | 1x16's | 065130 | PKR 603.19 | PKR 37.70/tablet | Near median |
| Malavel | Artemether | 40 mg | Tablet | 8's | 069818 | PKR 497.64 | PKR 62.21/tablet | Near median |
| Malavel | Artemether | 80 mg | Tablet | 4's | 069819 | PKR 414.70 | PKR 103.68/tablet | Near median |
| Malavel | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6`s | 069819 | PKR 439.50 | PKR 73.25/tablet | 33% below median |
| Neodrop-D | Cholecalciferol | 5 mg/mL | Injection | 5`sx1ml | 119431 | PKR 977.80 | PKR 195.56/mL | 6% above median |
| Neodrop-D | Cholecalciferol | 5 mg/mL | Injection | 1`sx1ml | 119431 | PKR 230.32 | PKR 230.32/mL | 24% above median |
| Omrel | Omeprazole | 20 mg | Capsule | 2x7's | 066444 | PKR 271.44 | PKR 19.39/capsule | Near median |
| Omrel | Omeprazole | 40 mg | Capsule | 2x7's | 066445 | PKR 471.25 | PKR 33.66/capsule | Near median |
| Omrel | Omeprazole | 40 mg | Solution for infusion | 1's | 119033 | PKR 619.59 | PKR 619.59/vial/unit | 37% above median |
| Omrel plus | Omeprazole | 20 mg | Capsule | 14's | 072847 | PKR 243.52 | PKR 17.39/capsule | 12% below median |
| Omrel plus | Omeprazole | 20 mg | Capsule | 10's | 072847 | PKR 197.53 | PKR 19.75/capsule | Near median |
| Orsal | Potassium chloride + Glucose | 1.5 g + 13.5 g | Sachet | 1x20 sachet | 069000 | PKR 364.58 | — | No comparator |
| Taxonec | Cefotaxime | 250 mg | Powder for injection | 1's | 097536 | PKR 105.47 | PKR 105.47/vial/unit | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.